Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Mehrdad Arjomandi, M.D. (ucsf)
Headshot of Mehrdad Arjomandi
Mehrdad Arjomandi

Description

Summary

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.

Official Title

Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening

Details

Keywords

Nodule Solitary Pulmonary, Non-small Cell Lung Cancer, Lung cancer screening, Biomarkers of lung cancer, Circulating tumor DNA, Low dose computed tomography of lung, Pulmonary nodule, Lung Neoplasms, Guardant Health ct-DNA LUNAR assay, Benign nodule on screening CT, Incidental benign nodule, Suspicious nodule, Suspicious incidental nodule

Eligibility

Locations

  • Zuckerberg San Francisco General Hospital and Trauma Center accepting new patients
    San Francisco California 94110 United States
  • San Francisco VA Medical Center accepting new patients
    San Francisco California 94121 United States
  • University of California, San Francisco accepting new patients
    San Francisco California 94122 United States

Lead Scientist at University of California Health

  • Mehrdad Arjomandi, M.D. (ucsf)
    Dr. Arjomandi grew up in Ahvaz, a small city in Southwestern Iran, and moved to the United States in 1986 in the aftermath of Iranian revolution (1979), Iraq's invasion of Iran (1980-88), and his family displacement inside Iran (1980-83).

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03774758
Study Type
Observational [Patient Registry]
Participants
Expecting 590 study participants
Last Updated